Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
GI-4000
i
Other names:
GI-4000, GI 4000, GI 4000 Tarmogen product, inactivated recombinant S. cerevisiae expressing mutant Ras protein, GI4000
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
ImmunityBio
Drug class:
RAS inhibitor
Related drugs:
‹
RMC-6236 (3)
JZP815 (2)
RMC-7977 (2)
IODVA1 (1)
NEO100 (1)
DO-2 (0)
antroquinonol (0)
KY1022 (0)
PRLX 93936 (0)
RMC-6236 (3)
JZP815 (2)
RMC-7977 (2)
IODVA1 (1)
NEO100 (1)
DO-2 (0)
antroquinonol (0)
KY1022 (0)
PRLX 93936 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (NCT03554109)
Phase 2
ImmunityBio, Inc.
ImmunityBio, Inc.
Withdrawn
Phase 2
ImmunityBio, Inc.
Withdrawn
Last update posted :
02/21/2025
Initiation :
09/01/2018
Primary completion :
06/01/2020
Completion :
02/09/2022
HER-2 • ER • PGR
|
HER-2 overexpression • HER-2 amplification
|
5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (NCT03387085)
Phase 1/2
ImmunityBio, Inc.
ImmunityBio, Inc.
Active, not recruiting
Phase 1/2
ImmunityBio, Inc.
Active, not recruiting
Last update posted :
09/27/2023
Initiation :
03/16/2018
Primary completion :
09/01/2023
Completion :
10/01/2023
HER-2 • ER • PGR
|
HER-2 overexpression • HER-2 amplification • PGR expression
|
Avastin (bevacizumab) • cisplatin • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
GI-4000 With Adoptive Transfer in Pancreatic Cancer (NCT00837135)
Phase 1
University of Pennsylvania
University of Pennsylvania
Withdrawn
Phase 1
University of Pennsylvania
Withdrawn
Last update posted :
08/17/2016
Initiation :
01/01/2008
Primary completion :
10/01/2009
Completion :
10/01/2009
KRAS
|
KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12 • KRAS Q61L • KRAS expression
|
GI-4000
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer (NCT00300950)
Phase 2
GlobeImmune
GlobeImmune
Completed
Phase 2
GlobeImmune
Completed
Last update posted :
04/06/2015
Initiation :
01/01/2006
Primary completion :
02/01/2015
Completion :
02/01/2015
RAS
|
RAS mutation
|
gemcitabine • GI-4000
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login